NCT Number: NCT00004697
Randomized Study of the Use of Intravenous Choline Supplementation in Long Term Total Parenteral Nutrition
OBJECTIVES:
I. Determine whether intravenous choline supplementation will reverse the hepatic steatosis and improve liver function in patients who receive long term total parenteral nutrition.
Looking for future studies?
Notify MeKey information
Conditions
Age range
16 year–74 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
PROTOCOL OUTLINE:
This is a randomized, double blind, placebo controlled study.
Patients receive either daily choline chloride in their total parenteral nutrition (TPN) solution or their usual TPN. The TPN is given intravenously over a 12 hour period beginning at approximately 9 PM nightly. Therapy continues for 24 weeks. Adjustments in the daily dose of choline provided may be required based on plasma free choline levels and patient tolerance. Additionally, all patients record the type and amount of their food intake on a daily basis.
Patients are followed every 2 weeks during the first 6 weeks, then every 4 weeks beginning with week 12 for the remainder of the 24 weeks, and then again at week 34.
Completion date provided represents the completion date of the grant per OOPD records
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Receiving nightly total parenteral nutrition (TPN) for greater than 70% of nutritional needs for a minimum of 8 weeks prior to study entry; Receiving no greater than 38 kcal/kg/day/ideal body weight; Receiving lipid emulsion as part of TPN regimen
Expected to require TPN for at least 34 weeks after study entry
Hepatic steatosis documented by prestudy CT scan
Consistent daily amount of intravenous amino acids, dextrose, or lipid received for 3 weeks prior to study entry
--Prior/Concurrent Therapy--
No concurrent cholinergic medications
--Patient Characteristics--
Hepatic: Albumin at least 3.5 g/dL; No hepatic failure; PT no greater than 2 times upper limit of normal
Renal: No renal failure requiring hemo- or peritoneal dialysis
Other: No AIDS; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception
Treatment and study plan
Sponsors and collaborators
Lead sponsor
University of Texas
Other
Registry information
Important dates
- Study start
- 1997
- Study completion
- 1999
- First posted
- Feb 25, 2000
- Registry last updated
- Mar 25, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
NCT02520609
Digestive System Diseases, Fatty Liver
Bethesda, Maryland, United States
View Trial DetailsVitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
NCT00862433
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsA Pathophysiological Study of the Postprandial Human Liver (PLS)
NCT03849235
Cirrhosis, Digestive System Diseases
Hvidovre, Capital Region Denmark, Denmark
View Trial DetailsProbiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults NAFLD Patients (DELI_NAFLD Study)
NCT05804422
Body Weight, Digestive System Diseases
Kyiv, Ukraine
View Trial Details